• As of 31 July 2021, 32,187,823 doses of COVID-19 vaccines had been administered. A total of 50,463 adverse events following immunization (AEFI) were reported to the Integrated Health Information System of Argentina (SIISA).
    Details, by vaccine, are shown in the following table:

Source: Fourteenth Vaccine Safety Surveillance Report, Ministry of Health of Argentina

Of total AEFI reported, 136, or 0.3%, were considered serious events (cases requiring hospitalization), of which 46 were associated with the AstraZeneca/Covishield vaccine, 15 with the Sinopharm vaccine, and 75 with the Sputnik V vaccine.

Of the events classified as related events, fever and headache with myalgia and arthralgia were the most frequent diagnoses. 




  • As of 3 September 2021, 37,153,868 doses of the COVID-19 vaccine of Pfizer-BioNTech, 13,057,703 doses of the Moderna vaccine, and 2,784,340 doses of the AstraZeneca and Covishield vaccine (AstraZeneca manufactured by the Serum Institute of India) had been administered.
  • There were 14,743 individual reports of one or more adverse events following immunization (0.027% of doses administered). Of these, 4,005 were considered serious events (0.007% of doses administered).
  • A total of 39,247 AEFI were reported (of which 14,743 were for one or more events). The most frequently reported AEFI were injection-site reactions, paresthesia, headache, pruritus, dyspnea, fatigue, nausea, etc.


An analysis of 676 of the 678 cases of myocarditis/pericarditis, with indication of the vaccine administered, is shown below:

Source: Public Health Agency of Canada. Canadian COVID-19 vaccine safety report. Ottawa: Public Health Agency of Canada; September 10, 2021. Data reproduced by PAHO/WHO. 

  • Share: